MedPath

CAB-AXL-ADC Safety and Efficacy Study in Adults with NSCLC

Phase 2
Active, not recruiting
Conditions
Non-Small-Cell Lung Cancer
Interventions
Biological: PD-1 inhibitor
Registration Number
NCT04681131
Lead Sponsor
BioAtla, Inc.
Brief Summary

The objective of this study is to assess safety and efficacy of CAB-AXL-ADC in NSCLC

Detailed Description

This is a multi-center, open-label, Phase 2 study designed to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity of BA3011, a conditionally active biologic (CAB) AXL-targeted antibody drug conjugate (CAB-AXL-ADC), alone and in combination with PD-1 inhibitor in patients with metastatic non-small cell lung cancer (NSCLC).

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
240
Inclusion Criteria
  • Patients must have measurable disease.
  • Age ≥ 18 years
  • Adequate renal function
  • Adequate liver function
  • Adequate hematological function
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Life expectancy of at least three months.
Exclusion Criteria
  • Patients must not have clinically significant cardiac disease.
  • Patients must not have known non-controlled CNS metastasis.
  • Patients must not have had prior therapy with a conjugated or unconjugated auristatin derivative/vinca-binding site targeting payload.
  • Patients must not have a history of ≥ Grade 3 allergic reactions to mAb therapy as well as known or suspected allergy or intolerance to any agent given during this study.
  • Patients must not have had major surgery within 4 weeks before first BA3011
  • Patients must not have known human immunodeficiency virus (HIV) infection, active hepatitis B and/or hepatitis C.
  • Patients must not be women who are pregnant or breast feeding.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
CAB-AXL-ADC (BA3011)CAB-AXL-ADCCAB-AXL-ADC (BA3011) alone
CAB-AXL-ADC (BA3011)+PD-1 inhibitorCAB-AXL-ADCCAB-AXL-ADC (BA3011) with PD-1 inhibitor
CAB-AXL-ADC (BA3011)+PD-1 inhibitorPD-1 inhibitorCAB-AXL-ADC (BA3011) with PD-1 inhibitor
Primary Outcome Measures
NameTimeMethod
Confirmed Objective Response Rate (ORR) per RECIST v1.1Up to 24 months

Proportion of patients who achieve a confirmed CR or PR according to RECIST v1.1

Incidence of Adverse Events (AEs)or Serious Adverse Events (SAEs) as assessed by CTCAE v4.03/v5Up to 24 months

Measured by frequency and severity of adverse events as assessed by CTCAE v4.03/v5

Secondary Outcome Measures
NameTimeMethod
Duration of response (DOR)Up to 24 months

Time from the first documented OR until the first documented disease progression or death (due to any cause), whichever occurs first

Progression-free survival (PFS)Up to 24 months

Time from the first dose of IP until the first documentation of disease progression or death due to any cause, whichever occurs first.

Best overall response (BOR)Up to 24 months

All post-baseline disease assessments that occur prior to the initiation of subsequent anticancer therapy

Disease control rate (DCR)Up to 24 months

Proportion of patients with a best overall response of confirmed CR, confirmed PR, or stable disease (SD) ≥ 12 weeks.

Time to response (TTR)Up to 24 months

Time from the first dose of investigational product until the first documentation of OR.

Percent change from baseline in target lesion sum of diametersUp to 24 months
Overall survival (OS)Up to 24 months

Time from the first dose of BA3021 treatment until death due to any cause.

Trial Locations

Locations (59)

City of Hope - Duarte

🇺🇸

Duarte, California, United States

University of California Irvine Medical Center (UCIMC) - Chao Family Comprehensive Cancer Center

🇺🇸

Irvine, California, United States

California Research Institute

🇺🇸

Los angeles, California, United States

USC Norris

🇺🇸

Los angeles, California, United States

Cedars-Sinai

🇺🇸

Los Angeles, California, United States

University of California, San Diego (UCSD) - Moores Cancer Center

🇺🇸

San Diego, California, United States

American Institute of Research

🇺🇸

Whittier, California, United States

University of Colorado Anschutz Medical Campus

🇺🇸

Aurora, Colorado, United States

Florida Cancer Specialists & Research Institute

🇺🇸

Fort Myers, Florida, United States

Florida Cancer Specialist

🇺🇸

Saint Petersburg, Florida, United States

Scroll for more (49 remaining)
City of Hope - Duarte
🇺🇸Duarte, California, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.